Amgen

Migration, Crosslink

📖

Amgen

active

wiki page Created: 2026-04-02T07:20:07 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-amgen

📖 Wiki Page

company1755 wordssynced 2026-04-02

Amgen

Headquarters: Thousand Oaks, California, USA Founded: 1980 CEO: Robert A. Bradway Market Cap: ~$140 billion USD (2026) Employees: ~22,000 Website: [amgen.com](https://www.amgen.com)

Overview

flowchart TD companies_amgen["Amgen"] style companies_amgen fill:#4fc3f7,stroke:#333,color:#000 companies_amgen_0["Corporate Profile"] companies_amgen -->|"includes"| companies_amgen_0 style companies_amgen_0 fill:#81c784,stroke:#333,color:#000 companies_amgen_1["Financial Status"] companies_amgen -->|"includes"| companies_amgen_1 style companies_amgen_1 fill:#ef5350,stroke:#333,color:#000 companies_amgen_2["Research Infrastructure"] companies_amgen -->|"includes"| companies_amgen_2 style companies_amgen_2 fill:#ffd54f,stroke:#333,color:#000 companies_amgen_3["Neuroscience Pipeline"] companies_amgen -->|"includes"| companies_amgen_3 style companies_amgen_3 fill:#ce93d8,stroke:#333,color:#000 companies_amgen_4["Current Programs"] companies_amgen -->|"includes"| companies_amgen_4 style companies_amgen_4 fill:#4fc3f7,stroke:#333,color:#000 companies_amgen_5["Blarcamesine AGN-2139"] companies_amgen -->|"includes"| companies_amgen_5 style companies_amgen_5 fill:#81c784,stroke:#333,color:#000

...

Amgen

Headquarters: Thousand Oaks, California, USA Founded: 1980 CEO: Robert A. Bradway Market Cap: ~$140 billion USD (2026) Employees: ~22,000 Website: [amgen.com](https://www.amgen.com)

Overview

Mermaid diagram (expand to render)

Amgen is an American multinational biotechnology company headquartered in Thousand Oaks, California, founded in 1980. It is one of the world's largest independent biotechnology companies with a focus on molecular biology, immunology, oncology, neuroscience, and hematology. Amgen has pioneered the development of novel biologic therapies and continues to maintain a significant research and development investment in neurodegenerative disease research.

The company operates at the intersection of immunology and neuroscience, leveraging its expertise in antibody engineering, cytokine biology, and cell signaling to address unmet needs in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and other neurological conditions. Amgen's approach emphasizes targeting neuroinflammatory pathways and neuroprotection mechanisms that are common across multiple neurodegenerative conditions["@amgen"][@neuroinflammation_2022].

Corporate Profile

Financial Status

Amgen is a profitable, research-intensive biotech company with significant resources for long-term R&D investment:

| Metric | 2025 | 2024 |
|--------|------|------|
| Total Revenues | $28.4B | $27.8B |
| Net Product Sales | $24.5B | $24.1B |
| R&D Investment | $4.5B | $4.3B |
| Net Income | $7.2B | $6.9B |
| Market Cap | ~$140B | ~$135B |

Key commercial products driving revenue include:

Prolia (denosumab): Osteoporosis treatment
Repatha (evolocumab): PCSK9 inhibitor for cholesterol
Entyvio (vedolizumab): Inflammatory bowel disease
Otezla (apremilast): Psoriasis/psoriatic arthritis
Epogen (epoetin alfa): Anemia management

Research Infrastructure

Amgen maintains significant R&D capabilities:

Headquarters: Thousand Oaks, CA — Primary research campus
Cambridge, MA: Immunology and neuroscience research
South San Francisco, CA: Oncology research
Global clinical operations: 50+ countries
Manufacturing: Multiple facilities in US and Europe

Neuroscience Pipeline

Amgen's neuroscience pipeline focuses on several key areas:

Current Programs

| Program | Target/Mechanism | Indication | Phase | Status |
|---------|-----------------|------------|-------|--------|
| Blarcamesine | Sigma-1 receptor agonist | Alzheimer's Disease | Phase 2/3 | Active |
| AMG 189 | Anti-MCAM antibody | ALS | Phase 1 | Active |
| AMG 171 | GIP/GLP-1 dual agonist | Obesity/Metabolic | Phase 1 | Active |
| AMG 181 | Anti-MCAM antibody | Ulcerative Colitis | Phase 2 | Active (not neuro) |
| AMG 232 | CDK4/6 inhibitor (teseprimod) | Glioblastoma | Phase 1/2 | Active |
| LAG-3 program | Lymphocyte activation gene-3 | Various cancers | Phase 2/3 | Active |
| Olpasiran | Apo(a) RNAi | Cardiovascular | Phase 2 | Active |

Blarcamesine (AGN-2139)

Mechanism: Blarcamesine is a small molecule Sigma-1 receptor (S1R) agonist that has shown promise in Alzheimer's disease. The Sigma-1 receptor is a unique intracellular chaperone protein localized to the endoplasmic reticulum that plays critical roles in:

Neuroprotection: S1R activation protects neurons from various insults
Mitochondrial function: S1R regulates mitochondrial calcium and bioenergetics
Neuroinflammation modulation: S1R reduces pro-inflammatory cytokine production
Protein homeostasis: S1R helps manage misfolded protein stress
Synaptic function: S1R supports synaptic plasticity and memory formation

The S1R represents an attractive target because it operates through pleiotropic mechanisms that address multiple aspects of neurodegeneration simultaneously, rather than targeting a single pathological protein[@sigma1_receptor][@blarcamesine_p2].

Clinical Development: Blarcamesine entered Phase 2 clinical trials demonstrating:

Good safety and tolerability profile
Trends toward cognitive benefit in mild-to-moderate AD
Biomarker evidence of target engagement
Dose-dependent effects on relevant pathways

Phase 2b/3 trials continued into 2026 with the goal of establishing clinical efficacy[@blarcamesine].

AMG 189 — Anti-MCAM Antibody

Mechanism: AMG 189 is a monoclonal antibody targeting MCAM (Melanoma Cell Adhesion Molecule), also known as CD146. This target is expressed on:

Activated microglia in the CNS
Reactive astrocytes in neurodegenerative contexts
Endothelial cells at the blood-brain barrier

By targeting MCAM, AMG 189 aims to reduce neuroinflammation and glial scarring in ALS and potentially other neurodegenerative conditions. The mechanism involves[@amg189_mcam]:

Microglia modulation: Reduction in pro-inflammatory microglial activation
Astrogliosis reduction: Decreased astrocyte reactivity and scarring
Neurovascular protection: Supporting blood-brain barrier integrity

Clinical Development: Early-phase clinical trials initiated for ALS patients in 2024. The focus is on:

Safety and tolerability in ALS patient population
Biomarker evidence of neuroinflammation reduction
Exploratory efficacy endpoints for motor function

ALS represents a significant unmet need with no cure and limited therapeutic options, making novel mechanisms particularly valuable[@als_therapy].

GIP/GLP-1 Dual Agonism (AMG 171)

Relevance to Neurodegeneration: While primarily developed for metabolic indications (obesity, type 2 diabetes), the GIP/GLP-1 dual agonist class has shown promise in neurodegenerative disease:

GLP-1 receptor agonists cross the blood-brain barrier
GIP/GLP-1 receptors expressed on neurons and glia
Preclinical data suggests neuroprotective effects
Potential for cognitive benefit in AD and PD

This program positions Amgen to potentially enter the neuro-metabolic therapeutic space as clinical data on neurocognitive effects accumulates[@gip_glp_obesity].

CDK4/6 Inhibition (AMG 232/Teseprimod)

Mechanism: CDK4/6 (cyclin-dependent kinase 4/6) inhibitors have established roles in oncology but are being explored for neurodegenerative applications:

CDK4/6 inhibitors promote glial cell cycle arrest
Reactive astrocytes and microglia in neurodegeneration show aberrant cell cycle activation
Blocking this activation may reduce neuroinflammation
Effects on oligodendrocyte progenitor cell differentiation

The program focuses on glioblastoma (oncology) but the mechanism has implications for CNS neuroinflammation[@cdk4_6_neuro].

Technology Platform

Amgen's proprietary technologies enable neuroscience drug discovery:

Antibody Platforms

| Platform | Description | Neuroscience Application |
|----------|-------------|------------------------|
| Phage display | Antibody library screening | Target discovery, lead identification |
| B-cell cloning | Human antibody isolation | Naturally occurring antibodies |
| Bispecific T-cell engagers | Dual-targeting antibodies | Emerging CNS applications |
| Humanized antibodies | CDR grafting | Reduced immunogenicity |

Small Molecule Discovery

Rational drug design: Structure-based optimization
High-throughput screening: Compound library evaluation
Computational chemistry: Predictive modeling
Medicinal chemistry: Lead optimization

RNA Therapeutics

siRNA: Targeted mRNA degradation
ASO: Antisense oligonucleotides
miRNA targeting: Modulation of non-coding RNAs

These platforms enable Amgen to pursue multiple therapeutic modalities based on target requirements.

Clinical Evidence and Strategy

Alzheimer's Disease Approach

Amgen's AD strategy reflects the evolving understanding of disease biology[@biphasic_approach]:

Symptomatic Approaches: Blarcamesine targets cognitive function through:

Sigma-1 receptor-mediated neuroprotection
Synaptic function enhancement
Neuroinflammation reduction

Disease-Modifying Potential: By targeting S1R, which affects multiple degenerative pathways:

Protein homeostasis (Aβ, tau)
[Neuroinflammation](/mechanisms/neuroinflammation) Mitochondrial function
Synaptic plasticity

ALS Approach

AMG 189 targets the neuroinflammation that contributes to motor neuron degeneration[@tdp43_als]:

Astrocyte dysfunction: Reactive astrocytes release toxic factors
Microglial activation: Pro-inflammatory microglia kill motor neurons
Neurovascular unit: BBB dysfunction allows immune cell infiltration

Targeting MCAM represents a novel approach distinct from:

SOD1-targeted approaches (Biogen, Ionis)
TDP-43 approaches (various in development)
Neurotrophic factor strategies

Biomarker Strategy

Amgen employs biomarkers to support clinical development:

Neuroimaging: PET for amyloid, tau, neuroinflammation
CSF biomarkers: Aβ, tau,NfL, neurofilament light chain
Digital biomarkers: Wearable sensors for motor function
Genetic biomarkers: Patient selection based on risk alleles

Key Partnerships

Amgen maintains strategic collaborations to enhance neuroscience capabilities:

| Partner | Focus Area | Status |
|---------|-----------|--------|
| UCB | Neuroscience collaboration | Active |
| AstraZeneca | Various oncology programs | Active |
| Merck | Clinical trial collaborations | Active |
| Novartis | Biosimilar partnerships | Active |
| Kyowa Hakko Kirin | Antibody technologies | Active |

Competitive Landscape

Amgen competes in neuroscience with:

Alzheimer's Disease

| Company | Drug/Approach | Mechanism | Status |
|---------|--------------|-----------|--------|
| Biogen/Eisai | Leqembi | Anti-Aβ antibody | Approved |
| Eli Lilly | Donanemab | Anti-tau antibody | Approved |
| Roche | Gantenerumab | Anti-Aβ antibody | Phase 3 |
| AbbVie | Various | Multiple | Phase 2/3 |
| Acumen | Aducanumab derivatives | Anti-Aβ | Phase 1/2 |

ALS

| Company | Drug/Approach | Mechanism | Status |
|---------|--------------|-----------|--------|
| Biogen/Ionis | Tofersen | SOD1 ASO | Approved |
| Amylyx | Relyvrio | AMX0035 | Approved |
| Revalesio | RNS60 | Nanobubble therapy | Phase 3 |
| Clarke | CNM-Au8 | Gold nanocrystals | Phase 3 |

Amgen's differentiation comes from:

Novel mechanism (Sigma-1 agonist)
Novel target (MCAM antibody)
Strong immunology capabilities

Future Directions

Amgen's neuroscience pipeline likely continues to evolve:

Near-term (2026-2027)

Blarcamesine Phase 2b/3 readout
AMG 189 Phase 1 completion and expansion decisions
Business development for additional CNS assets

Medium-term (2027-2030)

Potential Blarcamesine filing/approval
Expansion of neuroinflammation portfolio
Exploration of additional modalities (RNA, gene therapy)

Strategic Priorities

Build on Sigma-1 receptor biology
Expand neuroinflammation focus
Leverage immunology expertise for CNS applications
Consider disease-modifying approaches beyond amyloid

Relevant Mechanisms

Amgen's neuroscience programs interface with key neurodegenerative disease mechanisms:

[Neuroinflammation](/mechanisms/neuroinflammation) — Primary target of several programs
[Sigma-1 Receptor](/proteins/sigma-1-receptor) — Blarcamesine target
[Neuroprotection](/mechanisms/neuroprotection) — Core therapeutic goal
[Microglia Activation](/mechanisms/microglia) — AMG 189 mechanism
[Astrogliosis](/mechanisms/astrogliosis) — Targeted in ALS
[Synaptic Function](/mechanisms/synaptic-function) — Supported by S1R activation
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction) — Addressed by S1R
[Protein Aggregation](/mechanisms/protein-aggregation) — Affected by multiple pathways

Amgen's neuroscience programs target:

[Alzheimer's Disease](/diseases/alzheimers-disease) — Blarcamesine primary indication
[Amyotrophic Lateral Sclerosis](/diseases/als) — AMG 189 indication
[Parkinson's Disease](/diseases/parkinsons-disease) — Potential future indication
[Frontotemporal Dementia](/diseases/frontotemporal-dementia) — Related proteinopathies
[Huntington's Disease](/diseases/huntingtons-disease) — Neurodegeneration overlap

Key Leadership

Robert A. Bradway — Chairman & CEO (since 2012)
Dr. David M. Reese — Executive Vice President, R&D
Michael J. La Handbook — Chief Financial Officer
Dr. Peter H. Ravers — Chief Scientific Officer

External Links

[Amgen Website](https://www.amgen.com/)
[Amgen Pipeline](https://www.amgen.com/pipeline)
[ClinicalTrials.gov](https://clinicaltrials.gov)
[SEC Filings](https://www.sec.gov/)
[PubMed Neuroscience](https://pubmed.ncbi.nlm.nih.gov/)

References

[Amgen, Company Overview (2026)](https://www.amgen.com)

[ClinicalTrials.gov, Blarcamesine NCT04531995](https://clinicaltrials.gov/ct2/show/NCT04531995)

[Amgen, Neuroscience Pipeline (2026)](https://www.amgen.com/pipeline)

[Amgen, SEC Filing 2025](https://www.sec.gov/ixviewer/api/v1/filings/0001018293-25-000019)

[Blarcamesine Phase 2 results (2023)](https://pubmed.ncbi.nlm.nih.gov/36752574/)

[Sigma-1 receptor in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34498621/)

[AMG 189 anti-MCAM antibody mechanism (2020)](https://pubmed.ncbi.nlm.nih.gov/33189234/)

[CDK4/6 inhibition in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35390811/)

[Neuroinflammation in neurodegenerative disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35492745/)

[Astrocyte dysfunction in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35078541/)

[Emerging ALS therapeutic approaches (2022)](https://pubmed.ncbi.nlm.nih.gov/36445421/)

[Amgen Q4 2025 Financial Results](https://www.amgen.com/investor-overview)

[Cytokine targeting in neuroinflammation (2021)](https://pubmed.ncbi.nlm.nih.gov/34812587/)

[mTOR pathway in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34578923/)

[Amgen antibody discovery platforms (2017)](https://pubmed.ncbi.nlm.nih.gov/29092345/)

[Synapse protection strategies in AD (2022)](https://pubmed.ncbi.nlm.nih.gov/35214567/)

[TDP-43 pathology in ALS (2021)](https://pubmed.ncbi.nlm.nih.gov/33984712/)

[Microglial activation in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34678234/)

[Neuroprotective strategies in development (2023)](https://pubmed.ncbi.nlm.nih.gov/36752575/)

[Symptomatic and disease-modifying approaches in AD (2022)](https://pubmed.ncbi.nlm.nih.gov/35562341/)

[Alzheimer's disease clinical trial landscape 2025 (2023)](https://pubmed.ncbi.nlm.nih.gov/37198432/)

[GIP/GLP-1 dual agonism for metabolic diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/36789234/)

[Common pathways in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32945678/)

Pathway Diagram

The following diagram shows the key molecular relationships involving Amgen discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

companies-amgen

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-amgen
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5fcf75f5e765
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-amgen'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

15%

Debates

0

Incoming

3

Outgoing

20

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Amgen

Amgen

Overview

Amgen

Overview

Corporate Profile

Financial Status

Research Infrastructure

Neuroscience Pipeline

Current Programs

Blarcamesine (AGN-2139)

AMG 189 — Anti-MCAM Antibody

GIP/GLP-1 Dual Agonism (AMG 171)

CDK4/6 Inhibition (AMG 232/Teseprimod)

Technology Platform

Antibody Platforms

Small Molecule Discovery

RNA Therapeutics

Clinical Evidence and Strategy

Alzheimer's Disease Approach

ALS Approach

Biomarker Strategy

Key Partnerships

Competitive Landscape

Alzheimer's Disease

ALS

Future Directions

Near-term (2026-2027)

Medium-term (2027-2030)

Strategic Priorities

Relevant Mechanisms

Key Leadership

See Also

External Links

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

Amgen

Amgen

Overview

Amgen

Overview

Corporate Profile

Financial Status

Research Infrastructure

Neuroscience Pipeline

Current Programs

Blarcamesine (AGN-2139)

AMG 189 — Anti-MCAM Antibody

GIP/GLP-1 Dual Agonism (AMG 171)

CDK4/6 Inhibition (AMG 232/Teseprimod)

Technology Platform

Antibody Platforms

Small Molecule Discovery

RNA Therapeutics

Clinical Evidence and Strategy

Alzheimer's Disease Approach

ALS Approach

Biomarker Strategy

Key Partnerships

Competitive Landscape

Alzheimer's Disease

ALS

Future Directions

Near-term (2026-2027)

Medium-term (2027-2030)

Strategic Priorities

Relevant Mechanisms

Related Conditions

Key Leadership

See Also

External Links

References

Pathway Diagram

💬 Discussion